Product Name:Platelet Activation Panel

Adapting the principles of multiplexed flow cytometry, the Challenbio Platelet Activation Panel utilizes fluorochrome-conjugated monoclonal antibodies to identify specific surface antigens on platelets and leukocytes. Upon incubation with whole blood or platelet-rich plasma, these antibodies bind to their respective targets, forming stable antigen-antibody complexes. By analyzing the fluorescence intensity and light scatter characteristics of individual particles via flow cytometry, this assay allows for the precise quantification of platelet activation states and the detection of platelet-leukocyte aggregates in a rapid, high-throughput manner.

Clinical Significance

Thrombosis and Cardiovascular Risk Assessment

Monitoring CD62P expression provides an early warning for hypercoagulable states. Elevated levels are indicative of acute coronary syndromes, deep vein thrombosis (DVT), and stroke risk. Furthermore, assessing the integrity of CD42a/CD42b aids in diagnosing Bernard-Soulier syndrome, while evaluating CD41/CD61 function helps identify Glanzmann’s thrombasthenia.

Monitoring Antiplatelet Therapy

The assay is instrumental in evaluating the efficacy of antiplatelet drugs (e.g., aspirin, clopidogrel, or GPIIb/IIIa inhibitors). By quantifying the reduction in activation markers or receptor occupancy, clinicians can tailor dosages to balance bleeding risks against thrombotic protection, addressing issues of drug resistance.

Inflammation and Immune Thrombosis

The inclusion of CD45 allows for the analysis of platelet-immune cell interactions. Increased formation of

CD41+/CD45+ aggregates suggests a pro-inflammatory thrombotic environment, often seen in sepsis, autoimmune disorders, and vasculitis, providing insights into the crosstalk between the hemostatic and immune systems.